Antiphospholipid Antibody Syndrome in Pregnancy
Conditions
Brief summary
Study based on data concerning the first pregnancy treated and followed up after the diagnosis of oAPS in the NOH-APS cohort, according to clinical results already published; and on a thematic library collected and preserved at the time of the positive pregnancy test. ADAMTS 13 will be explored in the available samples defined above: ADAMTS13 antigen (presence of the molecule), ADAMTS13 activity (VWF proteolysis activity of the molecule), global autoantibodies against ADAMTS13 (plasma antibodies recognizing solid phase insolubilized ADAMTS13), these 3 parameters for the description of ADAMTS13 being measured using commercially available diagnostic kits, ELISA type, Technozyme® range, Technoclone, Vienna, Austria. The clinical endpoint evaluated will be the occurrence (yes/no) of preeclampsia, which is assessed globally, all subtypes combined. Then evaluated according to subtype: late preeclampsia from 34 weeks, early preeclampsia before 34 weeks, eclampsia (convulsions), HELLP syndrome, preeclampsia associated with the birth of a small-for-gestational-age child (defined at percentile 10 of the tables adjusted for gestational age and sex; severe: defined at percentile 3), preeclampsia associated with a retro-placental hematoma, ...
Interventions
OTHERTo study the prognostic value on the occurrence of pre-eclampsia, ADAMTS13 (ADAMTS13 protein and autoantibodies) in patients diagnosed with oAPS
ADAMTS13 activity, ADAMS13 antigen and anti-ADAMTS13 autoantibodies: U/ml.
Sponsors
Centre Hospitalier Universitaire de Nīmes
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Presence of frozen plasma samples from the positive pregnancy test blood sample. * Adult patients, included in the NOH-APS cohort, who have successfully initiated a new pregnancy after diagnosis of oAPS.
Exclusion criteria
* Absence of frozen plasma sample from the blood sample from the positive pregnancy test. * Patient who objected to the use of their data.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The quantification, in vitro, of the activity of ADAMTS13 | at inclusion (J0) | ADAMTS13 function, U/ml. |
| The quantification, in vitro, of ADAMTS13 antigen | at inclusion (J0) | ADAMTS13 antigen, U/ml. |
| The quantification, in vitro, of ADAMTS13 autoantibodies | at inclusion (J0) | ADAMTS13 autoantibodies, U/ml. |
Countries
France
Outcome results
None listed